Description

The BRCA2 Knockout DLD-1 Cell Line is a CRISPR/Cas9-edited knockout cell line engineered from the DLD-1 human colorectal adenocarcinoma cell line. This product provides a stable loss-of-function model for BRCA2, a critical tumor suppressor and mediator of homologous recombination repair. Disruption of the BRCA2 gene enables precise investigation of its roles in DNA damage response and genomic stability, making it an essential tool for cancer research and drug development.

DLD-1 is an epithelial colorectal adenocarcinoma cell line harboring well-characterized oncogenic mutations in APC, KRAS, and TP53. These background alterations drive key hallmarks of colorectal cancer, including aberrant Wnt signaling, constitutive MAPK pathway activation, and loss of p53-mediated checkpoint control. The introduction of a BRCA2 knockout onto this genetic landscape creates a physiologically relevant model to study DNA repair defects within a colorectal tumor context.

BRCA2 functions as a central scaffold for loading RAD51 recombinase onto RPA-coated single-stranded DNA, a crucial step in homologous recombination repair and replication fork protection. Its activity is regulated by upstream kinases such as ATM and ATR, as well as cyclin-dependent kinases and E2F transcription factors. BRCA2 interacts with PALB2, BRCA1, BARD1, and DSS1, and its loss disrupts RAD51 filament formation, leading to unrepaired DNA breaks, CHK2 and p53 activation, and apoptosis. The BRCA2 pathway is interconnected with the Fanconi anemia network via FANCD2 and FANCN.

In the DLD-1 background, BRCA2 knockout synergizes with existing APC, KRAS, and TP53 mutations to drive synthetic lethality paradigms, particularly with PARP inhibitors. This model recapitulates the genomic instability observed in BRCA2-deficient tumors, allowing researchers to study the impact of homologous recombination deficiency on tumor progression and therapeutic response in a colorectal adenocarcinoma setting. It also serves as a platform to investigate the role of BRCA2 in centrosome duplication and cell cycle checkpoints.

Typical applications include functional genomics, DNA repair pathway analysis, and screening for PARP inhibitor sensitivity. Researchers can validate BRCA2 knockout status via Western blotting and examine downstream markers such as ??H2AX and RAD51 foci formation. Complementary assays include homologous recombination reporter assays, cell viability assays under PARP inhibitor treatment, comet assays for DNA damage quantification, cell cycle analysis by flow cytometry, and Annexin V apoptosis assays. This cell line is also suitable for biomarker discovery and mechanism-of-action studies for emerging therapeutics. For further details, please contact Ascent Research.